MKM Partner Raises Price Target on Pfizer (PFE)

MKM Partners maintained a Buy on Pfizer (NYSE: PFE) and increased its price target to $29.00 (from $27.00).

"Our price target is based on what we consider to be a fair multiple, parity with the group 2013E multiple of 12.7x applied to 2013E PFE earnings of $2.26. Our target price is based on our 3D valuation framework. Pfizer scores below average on its 2012E-2016E pipeline and has the least patent exposure and a slightly below-average score on company-specific factors," said analyst Jon LeCroy, M.D.

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $25.35 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Chemung Financial (CHMG) Tops Q1 EPS by 44c
• HSBC Upgrades Johnson & Johnson (JNJ) to Buy, 'Steady outlook, low expectations'